Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

NCT02038036 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycythemia Vera

Interventions

DRUG: Best Available Therapy
DRUG: Ruxolitinib

Sponsor

Novartis Pharmaceuticals